Efficacy and safety of mirikizumab as maintenance therapy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 LUCENT-2 study

Research output

Research output per year 2022 2022 2022

• 1 Meeting Abstract

Research output per year

Research output per year

Search results

• 2022

  Efficacy and Safety of Mirikizumab As Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 Lucent-2 Study

  Dubinsky, M. C., Irving, P. M., Li, X. Y., Howaldt, S., Pokrotnieks, J., Krueger, K. A., Laskowski, J., Lissoos, T., Milata, J., Morris, N., Arora, V., Milch, C. & Sands, B. E., May 2022, In: Gastroenterology. 162, 7, p. S1393-S1394 2 p., 867e.

  Research output: Contribution to journal › Meeting Abstract › peer-review